Utilizing Intra- and Peritumoral Radiomics to Assess Ambiguous HER2 Status in Breast Cancer via Contrast-Enhanced Mammography - Takeaways - MDSpire

Utilizing Intra- and Peritumoral Radiomics to Assess Ambiguous HER2 Status in Breast Cancer via Contrast-Enhanced Mammography

  • By

  • Cong Xu

  • Juan Qiu

  • Shijie Zhang

  • Yuqian Chen

  • Xiaodong Wang

  • Haicheng Zhang

  • Qi Wang

  • Tongpeng Chu

  • Ziyin Li

  • Peng Lu

  • Haizhu Xie

  • Heng Ma

  • Nina Qu

  • Ning Mao

  • Jing Liu

  • Runpeng Chen

  • Jing Gao

  • April 29, 2026

  • 0 min

Share

  • 1

    The study evaluated the equivocal HER2 (IHC 2+) status in breast cancer using intra- and peritumoral radiomics features from contrast-enhanced mammography.

  • 2

    A total of 131 breast cancer patients were enrolled, divided into training, internal test, and prospective test cohorts for model evaluation.

  • 3

    The nomogram incorporating intratumoral and peritumoral signatures achieved optimal predictive performance with AUCs of 0.893 and 0.840 in internal and prospective cohorts, respectively.

  • 4

    Contrast-enhanced mammography (CEM) offers a non-invasive method to assess HER2 status, potentially reducing reliance on time-consuming FISH testing.

  • 5

    The study highlights the clinical applicability of radiomics in predicting HER2 status, bridging the gap between advanced imaging techniques and routine clinical practice.

Original Source(s)

Related Content